Skip to main content

Small molecule hdac6 inhibitors

Ref-Nr: TA-B74064


Kurzfassung

  • Cancer cells use an extracellular citrate supply as an important energy source and substrate for the synthesis of critical cellular building blocks (e.g. fatty acids). 
  • A highly specialized plasma membrane protein (pmCiC, plasma membrane citrate carrier) was found to be responsible for citrate uptake in cancer cells
  • pmCiC is a novel and specific marker and therapeutic target for cancer cells


Hintergrund

For malignant tumors to successfully grow and metastasize, cancer cells use an extracellular citrate supply as an important energy source and substrate for the synthesis of critical cellular building blocks (e.g. fatty acids). Several metabolomic studies indicate that blood citrate levels decrease in cancer pa- tients (e.g. lung, bladder, pancreas). Recent studies show that a significant portion of citrate is taken up by cancer cells from the extracellular space. In contrast, normal cells do not take up citrate except some specialized (liver, kidney, sperm) normal cells.


Bilder & Videos


Lösung

The inventors found a highly specialized plasma membrane protein (pmCiC, plamsamembranecitrate carrier) to be responsible for citrate uptake in cancer cells. PmCiC expression is detetcted in a wide variety of human cancer cell lines, as well as in human tumor tissue ­sections with differences in ex- pression levels among cancers, and within the different areas of individual cancers (invasion front and invading cells are often more stained that the cells in the central part of the tumor). The transporter is also present in normal prostate secretory cells (apically), but works in opposite directions, as citrate ex- porter, and is responsible for maintaining high extracellular citrate levels in the prostate gland. The spe- cialized normal cells (liver, kidney, sperm) that also take up citrate use a different channel (not pmCiC).


Vorteile

  • pmCiC is a novel and specific marker of cancercells
  • pmCiC expression correlates with tumor grade: the more aggressive regions of the ­cancer appear to have the most intense expression
  • pmCiC as new therapeutic target: inhibitors, openers, antibodies, cytotoxic drugs

Bayerische Patentallianz GmbH


089 5480177-0
kontakt@baypat.de
www.baypat.de
Adresse
Destouchesstr. 68
80796 München



Angebot Anbieter-Website


Kontakt | Geschäftsstelle

TransferAllianz e. V.
Christiane Bach-Kaienburg
(Geschäftsstellenleiterin)

c/o PROvendis GmbH
Schloßstr. 11-15
D-45468 Mülheim an der Ruhr